trending Market Intelligence /marketintelligence/en/news-insights/trending/nihpnhou5rvaqhkx9pwc3q2 content esgSubNav
In This List

Biohaven Pharmaceutical director resigns

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Biohaven Pharmaceutical director resigns

Biohaven Pharmaceutical Holding Co. Ltd. said Albert Cha notified the company of his intent to step down as the company's director, effective Sept. 7.

The company said Cha's resignation was not a result of any disagreement with the company or the board.

New Haven, Conn.-based Biohaven Pharmaceutical is a clinical-stage biopharmaceutical company that develops product candidates to treat neurological diseases, including rare disorders.